Vera Therapeutics Inc
NASDAQ:VERA

Watchlist Manager
Vera Therapeutics Inc Logo
Vera Therapeutics Inc
NASDAQ:VERA
Watchlist
Price: 46.62 USD -1.83%
Market Cap: $3B

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Vera Therapeutics Inc
NASDAQ:VERA
3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Vera Therapeutics Inc
Glance View

Market Cap
3B USD
Industry
Biotechnology

Vera Therapeutics Inc., founded with a vision to transform the treatment landscape for immunological diseases, operates at the intersection of biotechnology innovation and healthcare needs. Headquartered in the biotech hub of South San Francisco, the company relentlessly pursues therapeutic solutions to address unmet medical needs, focusing primarily on severe immunological conditions. Central to their approach is the identification and development of critical biological targets to modulate immune responses. Their flagship program, atacicept, underscores this strategy. As a recombinant fusion protein, atacicept is engineered to block both B lymphocyte stimulator (BLyS) and proliferation-inducing ligand (APRIL), crucial drivers of B cell activity, which are implicated in autoimmune diseases. This precision and specificity highlight Vera’s commitment to targeting root causes of diseases rather than merely treating symptoms. Commercial viability for Vera Therapeutics hinges on successful clinical trials and subsequent regulatory approvals, which pave the way for market entry and partnerships. By progressing atacicept through various phases of clinical development, the company aims to demonstrate its efficacy and safety, positioning the therapy as a game-changer for patients with conditions like IgA nephropathy. Their revenue strategy will largely depend on the therapy’s uptake by healthcare providers and reimbursement endorsements from insurance companies post-approval. Furthermore, by leveraging strategic alliances and fostering collaborations within the industry, Vera aims to expand its pipeline and optimize its commercial potential, thereby establishing a robust revenue stream anchored in cutting-edge science and patient-centric solutions.

VERA Intrinsic Value
11.58 USD
Overvaluation 75%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top